Diagnostics and therapeutics for glaucoma
AssigneesAlcon Inc., University of Iowa Research Foundation
InventorsAbbot Clark, John Fingert, Loretta McNatt, Edwin Stone, Wan-Heng Wang
Life of this patent
Estimating the term…
Abstract
Methods and compositions for diagnosing and treating glaucoma are disclosed.
Claims28
1-16. (canceled)
A method of identifying an anti-glaucomatous compound comprising:
- contacting a cell expressing a Wnt pathway component or a frizzled related protein gene product with a test compound;
- and
- detecting a level or bioactivity of said Wnt pathway component or said frizzled related protein gene product in the presence of the test compound;
- wherein an increase or decrease in the level or bioactivity of the Wnt pathway component or the frizzled related protein gene product in the presence of the test compound as compared to the level or bioactivity detected in the absence of the test compound identifies said test compound as an anti-glaucomatous compound.
A method of identifying an anti-glaucomatous compound comprising:
- contacting a cell sample with a test compound;
- and
- measuring a level or bioactivity of a Wnt responsive gene;
- wherein an increase in the level of the Wnt responsive gene in the presence of the test compound as compared to the level or bioactivity of the Wnt responsive gene in the absence of the test compound identifies said test compound as an anti-glaucomatous compound.
A method for treating glaucoma in a human subject, comprising administering to the subject, a therapeutically effective amount of a compound that modulates the level or bioactivity of a Wnt pathway component or frizzled related protein gene product.
A method for screening for a frizzled related protein agonist or antagonist comprising the steps of:
- a) combining a frizzled related protein polypeptide or bioactive fragments thereof, a frizzled related protein binding partner and a test compound under conditions wherein, but for the test compound, the frizzled related protein protein and frizzled related protein binding partner binding partner are able to interact;
- and
- b) detecting the extent to which a frizzled related protein/frizzled related protein binding partner complex is formed in the presence of the test compound, wherein an increased amount of complex formation in the presence of the test compound relative to in the absence of a test compound indicates that the test compound is a frizzled related protein agonist and a decreased amount of complex formation in the presence of the test compound relative to in the absence of the test compound indicates that the test compound is a frizzled related protein antagonist.
A method of claim 43, which additionally comprises the step of preparing a pharmaceutical composition from the test compound.
Dependencies are inferred from the claim text.